Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
Datamonitor HealthcarePharma intelligence |
1
White paper
Challenging outlook for contract manufacturers
By George GreenJune 2014
Datamonitor HealthcarePharma intelligence |
Datamonitor HealthcarePharma intelligence |
2
As f
featured in
W
f
t
r
e
a
f
h
m
DISCLAIMER While every car
facts, estimates
them to be relia
reference in rela
employees for a
anything contain
findings are Dat
has no obligatio
materially.
re is taken to en
s, and opinions s
able, are not gua
ation to the subj
any loss occasio
ned in or omitte
tamonitor's curr
on to update or a
nsure the accura
stated are base
aranteed. In par
ject matter. No
oned to any per
ed from the cont
rent opinions; th
amend the rese
George Gre
I work as anoutsourcing Datamonitorresearch andtechnologiesinterest in mas possible.
Before joinineating disordsystematic rconferencespsychology s
If you have qfindings withdirectly to thinfo@datam To find out mcontact us a email getclophone +44 2Visit our webOr follow us
acy of the inform
ed on informatio
rticular, it should
liability can be a
rson or entity ac
tent of this mate
hey are subject t
earch or to let an
een An
analyst in thand strategy
r since 2009,d manufactus, and health
making our se
ng Datamonitders researceview and p
s. I also devestart-up com
questions abhin this docume analysts. Sonitorhealthc
more about Dat:
oser@datamo20 7551 943bsite: www.don Twitter:
mation contained
n and sources w
d not be relied u
accepted by Da
cting or failing to
erial, or our conc
to change witho
nyone know if o
nalyst
he strategy tey content. Ha, I have writtering, clinical
hcare reform.ervice as eng
tor I worked h unit whereresented at i
eloped psychmpany.
bout the resement you canSimply emailcare.com.
Datamonitor
onitorhealthc30 datamonitorh@Datamonit
d in this materia
which, while we
upon as the sole
atamonitor, its d
o act as a result
clusions as state
out notice. Datam
our opinions cha
eam, managaving workeden reports ontrial data co
. I have a spegaging and in
at an obesitye I conductednternational
hometric tests
arch, data, an put your qu your questio
Healthcare,
care.com
healthcare.cotorHC
al, the
e believe
e source of
irectors, or
of
ed. The
monitor
ange
ing d at n contract llection ecial nteractive
y and d a
s at a
and uestions ons to
om
Datamonitor HealthcarePharma intelligence |
3
As f
featured in
Thea rapphamarphaoftedigi Georgecontracas settle The financi
industry, m
However, m
basis that p
continue cu
One of the
or strategic
business d
outsourcing
increasing
pastpid erma
rkets rmac
en act yea
e Green tct drug med as co
ial crisis of 2
mainly through
most industry
pharma com
utting in-hous
obvious way
c agreement
evelopment
g firmly rustli
interest to th
t decexpancontthat
ceutihievi
ar-ontakes a lomanufaculd be th
008 had a co
h the restrict
y observers a
panies are e
se capacity t
ys to cut in-h
with a contra
organization
ing the leave
hose looking
cade nsiontractt havical ming d
n-yeaook at thturer, anhought.
ooling effect
tion of ventur
are still forec
expected to s
to reduce fixe
house capaci
act manufact
n. With this in
es of Big Pha
for growth in
has an of serv
ve oumarkdoubar grohe futurend finds
on the drug
re capital fun
casting contin
seek further c
ed costs.
ty is to enter
turer, resear
n mind, and w
arma, the CM
n the next few
a see
vices utpackets, ble-owth
e for the a scene
developmen
nding for biot
nued growth
cost-savings
r into a trans
rch organizat
with the bree
MO market is
w years.
en
ced
h.
not
nt
techs.
on the
, and
actional
tion or
eze of
of
Datamonitor HealthcarePharma intelligence |
4
As f
featured in
Mp
Manuperfo
The conthe leadthird ofmediumDatamowill resCMOs i The overar
entry are fa
capitalize o
facilities an
providers is
solid and s
In addition,
investing in
ufactorm
ntract mding 10 cf the marm-sized ponitor hault in toun the co
rching long te
alling, and a
on rapid grow
nd equipmen
s consequen
emi-solid do
, manufactur
ncreasingly in
uring
manufactucompanirket. Thoprovideras identiugh con
oming fiv
erm trend in
large numbe
wth rates ove
t from the ph
ntly high, esp
se forms. De
ring demand
n niche thera
g: pre
uring maies accouousands rs comprfied seve
nditions fve years.
the industry
er of new pla
er the past de
harma indust
pecially in the
eclining marg
is also shifti
apeutic areas
essur
arket is funt for aof small
rise the reral factofor many
is commodit
yers entered
ecade. Many
try. Competit
e most well-s
gins are an o
ng. The phar
s and orphan
re to
fragmenaround al- to remaindeors whicy of thes
tization. Barr
d the market
y did so by ac
tion between
served segm
obvious resul
rma industry
n drugs.
nted; a
er. ch e
riers to
to
cquiring
n
ents of
lt.
y is
Datamonitor HealthcarePharma intelligence |
5
As f
featured in
F
Figure 1: F
Sources: Data
As figure 1
markedly, a
Many desig
lag in appro
projects.
The decline
emerging m
products di
manufactur
creating a t
FDA orpha
amonitor Orpha
illustrates, t
although app
gnations are
ovals is expe
e of the block
markets and
istributed to t
ring. Econom
threat to CM
an drug a
n Drug Trends,
he number o
provals have
granted up t
ected. Increa
kbuster is als
increasing re
those marke
mies of scale
Os. These fa
pprovals a
FDA Law Blog
of FDA orpha
not yet show
to a decade
asingly, dema
so driving thi
eimburseme
ets, which wil
are severely
actors are dr
and desig
an designatio
wn a corresp
before targe
and will be fo
is trend. Gro
nt will extend
l add to dem
y impacted o
riving CMOs
gnations.
ons has risen
ponding expa
t approval so
or small-batc
wing wealth
d the range o
mand for sma
on these proj
to seek prof
n
ansion.
o a time
ch
in
of
all-batch
ects
fits in
Datamonitor HealthcarePharma intelligence |
6
As f
featured in
more speci
products, a
While highe
at work, wh
Yields are
smaller rea
modular co
companies
that captive
patent expi
capacity as
Divestment
By contrast
often spurr
more recen
corporation
Significant
240,000 sq
Cork. In Oc
Waterford s
Much of thi
growth in b
underlying
pharma co
expensive j
and Weste
Switzerland
Swiss franc
Biotech fun
Pricewater
biotech VC
ialized manu
and biologics
er margins a
hich will ultim
increasing, m
actor vessels
onstruction a
s to flexibly sc
ely-owned ca
iries on top-s
s sales volum
t of in-house
t, in recent y
red on by tax
ntly, the UK).
n tax in Europ
activity inclu
quare foot ex
ctober Genzy
site.
is capacity w
biologics, gen
threat to CM
mpany's cos
jurisdictions.
rn Europe it
d such as Lo
c over the pa
nding trends
houseCoope
C activity has
ufacturing are
s.
are available
mately lead to
meaning that
s. In parallel,
re lowering b
cale their cap
apacity is als
selling brand
mes decline w
e facilities has
years many in
x incentives (
. Meanwhile
pe and has a
udes Lilly’s an
xpansion of a
yme announ
will be taken u
nerics, and e
MOs is that du
st-base will b
. Ireland corp
is likely to be
onza and Aen
ast two to thr
also present
ers and the U
recovered fr
eas such as
in the biolog
o commoditiz
t the same o
evolving sin
barriers to en
pacity. Grow
so expanding
s are also ac
with generic
s historically
nnovators ha
(for example
e, Ireland has
attracted sev
nnouncemen
a biopharmac
ced a €130 m
up by increas
emerging reg
ue to the fav
e lower than
poration tax i
e 25-35%. C
nova have be
ree years.
t challenges
US National V
rom a six yea
high potency
gics space, th
zation of biom
utput can be
gle-use tech
ntry, and allo
wing process
g. In the sma
cting to incre
entry.
driven contr
ave invested
in Singapore
s among the
veral large inv
nt to invest €
ceutical man
million expan
sing volume
ions. The co
vorable tax co
n that of CMO
is 12.5%, wh
CMOs with op
een hurt by t
to the indust
Venture Cap
ar low in 200
y APIs, steril
he same forc
manufacturin
e achieved w
nologies and
owing pharma
efficiencies
ll molecule s
ease effective
ract manufac
in new facilit
e, Puerto Ric
lowest rates
vestments.
€330 million i
ufacturing fa
nsion at their
demands du
ontinuing and
onditions, the
O's based in
hereas in the
perations in
the strength o
try. Accordin
pital Associat
09 caused by
e
ces are
ng.
ith ever
d
a
mean
segment,
e
cturing.
ties,
co, and
s of
n a
acility in
r
ue to
d
e
more
US,
of the
ng to
tion,
y the
Datamonitor HealthcarePharma intelligence |
7
As f
featured in
financial cr
2003, see f
Figure 2:
Sources: http
National Vent
Furthermor
biotechs w
depend hea
knock-on e
on the basi
10 players,
risis. Even so
figure 2.
: Biotech V
://www.nvca.org
ture Capital Ass
re, insiders r
ith more adv
avily on outs
effect on CMO
is that their c
, leading to b
o, funding in
VC fundin
g/index.php?opt
sociation
eport that the
vanced produ
sourcing prov
Os. Biotechs
contract will b
better service
the first half
ng 2006-H
tion=com_docm
e funding is s
ucts. Lacking
viders, so the
s often emplo
be more valu
e.
of 2012 was
H1 2012.
man&task=doc_d
shifting to mo
g internal res
e trends are
oy smaller an
uable than w
s the lowest s
download&gid=
ore establish
ources, biote
likely to have
nd mid-sized
hen working
since
914
hed
echs
e a
CMOs,
with top
Datamonitor HealthcarePharma intelligence |
8
As f
featured in
A silVarious fac
continues t
demand. G
These mar
pharmaceu
opportunitie
slightly, wit
tier emergi
see rapid C
Nipro anno
As mention
novel produ
investment
specialist m
drug develo
to hit target
molecules.
in developm
properties
CMOs with
As R&D pro
have come
each drug.
novel dosa
impractical
consequen
and geogra
markets.
Conditions
offering. As
ver lictors will act
to grow, whic
Growth in em
rkets will ove
uticals for the
es for CMOs
th wage infla
ng economie
CMO market
ounced const
ned above, re
ucts which w
t is in oncolo
manufacturin
opment has
ts which can
Consequen
ment have hi
bring manufa
h specialist ca
oductivity ha
e to fore as in
Product diffe
age forms. Fo
to develop t
nce. To summ
aphies, favor
will be tough
s cost-cutting
iningto counterba
ch will drive c
erging marke
rwhelmingly
e foreseeable
s. Cost advan
tion and risin
es such as T
growth. For
truction of a
esearch and
will require sp
gics which a
g facilities. In
been taken,
nnot be modu
tly, an increa
igh molecula
acturing chal
apabilities.
as declined, t
nnovators se
erentiation is
or many phar
the capabiliti
marize, these
ring specializ
hest for sma
g continues,
g for salance these
clinical suppl
ets is anothe
dominate th
e future, whic
ntages of BR
ng property p
Thailand, Viet
example, in
new plant in
developmen
pecialist man
re often high
n addition, no
drug candid
ulated by the
asing proport
ar weight and
llenges, aga
the industry l
eek to squeez
s increasingly
rma compan
es in-house,
e growth driv
zed providers
ller CMOs, la
pharma com
some threats. Indu
ly and proces
er oft-quoted
e volume de
ch will again
RIC countries
prices. Conse
tnam, Cuba,
August 2012
Hai Phong,
nt is increasi
nufacturing te
h-potency AP
ow that the “
ates are incr
most “drug-
tion of small-
d greater lipo
in creating o
lifecycle man
ze as much a
y through ne
nies and biote
making outs
vers will act in
s and those i
acking a spe
mpanies are s
e ustry R&D sp
ss developm
reason for g
emand for
, create
s have narrow
equently, sec
and Argenti
2, Japanese
Vietnam.
ngly focusing
echniques. M
PIs, requiring
“low hanging
reasingly des
-like” small
-molecule pr
ophilicity. The
pportunities
nagement str
as possible o
ew delivery ro
echs, it will b
sourcing logi
n specific se
n emerging
ecialized serv
seeking to re
pending
ment
growth.
wed
cond-
na will
CMO,
g on
Much
g
fruit” of
signed
roducts
ese
for
rategies
out of
outes or
be
ical
gments
vice
educe
Datamonitor HealthcarePharma intelligence |
9
As f
featured in
the overhea
will engage
to a smalle
Although so
industry, th
companies
capability. T
differentiati
years.
BOXOUTSpecializ High poten
Narcotics
Solvent-ba
Drug deliv
Sterile pro
Process d
Implantab
ad of selectin
e in more pre
er group of pa
ome observe
his has yet to
s' cherry-pick
The messag
ion of service
T zed CMO s
ncy API (Ca
(DEA sched
ased produc
very product
oducts (prefi
evelopment
le dosage fo
ng and contr
eferred provid
artners.
ers have pre
o occur. M&A
king smaller p
ge for the con
es will be the
services
t 3)
uled substan
cts
ts
lled syringes
t
orms
racting with a
der arrangem
dicted of a w
A activity will
players or sit
ntract manufa
e key to succ
nces)
s, lyophilized
a large numb
ments, pushi
wave of conso
continue to b
tes to acquire
acturing indu
cess in the co
vials)
ber of operato
ng a larger v
olidation in th
be driven by
e a specific
ustry is clear
oming five to
ors, and
volume
he CMO
–
o 10
Datamonitor HealthcarePharma intelligence |
10
As f
featured in
Fur The COutloDatamonitpipeline prGermany,
Click here
rtheContracook to 2
tor patient-broducts for Italy, Spain
e to find out
er rect Biom2017 based foreca2011 to 202, and the UK
more abou
eadmanufa
ast of leadin20. CoverageK.
ut this repor
dingacturin
ng non-insue: US, Japan
rt >>
g…ng Mark
lin brands an, France,
ket
and
Datamonitor HealthcarePharma intelligence |
11
As f
featured in
A
Abo
DatamBringing yo
healthcare
Complete Our indepe
disease are
identify opp
insights to
Unique exWith teams
uniquely pl
reliable rec
Citeline, SC
share data
intelligence
Cutting-edAvailable th
intelligence
analysis off
market ass
out
monitoou a clearer,
market.
market coveendent resea
eas, compan
portunities an
respond with
pert capabis located acr
aced to unde
commendatio
CRIP Intellige
and resourc
e.
dge deliveryhrough single
e service that
fers the defin
sessment and
T
e
w
T
us
or Healtricher and m
erage
arch and ana
nies and strat
nd threats ar
h faster, mor
lities
ross develop
erstand local
ons. By work
ence and Inf
ces to produc
y
e reports or v
t features int
nitive platform
d strategic p
To find out mDatamonitor
email enquir
phone +44 2
website: ww
Twitter: @D
thcaremore respons
lysis provide
tegic issues,
rising from sh
e effective d
ed and emer
l healthcare
king closely w
forma Health
ce the most a
via subscript
tuitive design
m to enhance
lanning.
more about r Healthcare,
ries@datamo
20 7551 943
ww.datamonit
DatamonitorH
sive view of t
es extensive
, giving you t
hifting marke
ecision-mak
rging pharma
trends and p
with our partn
hcare, our ex
authoritative
tion to our sta
n and interac
e your produ
please cont
onitorhealthc
0
torhealthcare
HC
the pharma &
coverage of
the perspecti
et dynamics a
ing.
a markets, w
provide accur
ners at MedT
xperts are ab
and robust m
ate-of-the ar
ctive capabilit
uct managem
tact us at:
care.com
e.com
&
major
ive to
and the
we are
rate and
Track,
le to
market
rt online
ties, our
ment,